Lung cancer is one of the most frequently diagnosed cancers and is the leading cause of
cancer-related death worldwide. Non-small-cell lung cancer (NSCLC), a heterogeneous …

In the past decade, the characterization of non-small-cell lung cancer (NSCLC) into
subtypes based on genotype and histology has resulted in dramatic improvements in …

Background We assessed the efficacy and safety of programmed cell death 1 (PD-1)
inhibition with pembrolizumab in patients with advanced non–small-cell lung cancer …

The value of any new therapeutic strategy or treatment is determined by the magnitude of its
clinical benefit balanced against its cost. Evidence for clinical benefit from new treatment …

Purpose To provide evidence-based recommendations to update the American Society of
Clinical Oncology guideline on systemic therapy for stage IV non–small-cell lung cancer …

This report presents the recommendations of the WHO Expert Committee responsible for
updating the WHO Model Lists of Essential Medicines.. The goal of the meeting was to …

Purpose: Therapies targeted to the immune checkpoint mediated by PD-1 and PD-L1 show
antitumor activity in a subset of patients with non–small cell lung cancer (NSCLC). We have …

We report the preclinical evaluation of PF-06463922, a potent and brain-penetrant
ALK/ROS1 inhibitor. Compared with other clinically available ALK inhibitors, PF-06463922 …

These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for
Non–Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in …

One strategy for combating cancer-drug resistance is to deploy rational polytherapy up front
that suppresses the survival and emergence of resistant tumor cells. Here we demonstrate in …